Mary G Fowler1, Min Qin1, Susan A Fiscus1, Judith S Currier1, Patricia M Flynn1, Tsungai Chipato1, James McIntyre1, Devasena Gnanashanmugam1, George K Siberry1, Anne S Coletti1, Taha E Taha1, Karin L Klingman1, Francis E Martinson1, Maxensia Owor1, Avy Violari1, Dhayendre Moodley1, Gerhard B Theron1, Ramesh Bhosale1, Raziya Bobat1, Benjamin H Chi1, Renate Strehlau1, Pendo Mlay1, Amy J Loftis1, Renee Browning1, Terence Fenton1, Lynette Purdue1, Michael Basar1, David E Shapiro1, Lynne M Mofenson1. 1. From the Department of Pathology, Johns Hopkins University School of Medicine (M.G.F.), and the Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health (T.E.T.), Baltimore, and the Division of AIDS, National Institute of Allergy and Infectious Diseases (D.G., K.L.K., R. Browning, L.P.), and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (G.K.S.), National Institutes of Health, Bethesda - all in Maryland; the Center for Biostatistics in AIDS Research, Harvard T.H. Chan School of Public Health, Boston (M.Q., T.F., D.E.S.); the Retrovirology Core Laboratory, University of North Carolina School of Medicine, Chapel Hill (S.A.F., A.J.L.), and FHI 360, Durham (A.S.C.) - both in North Carolina; the UCLA Center for Clinical AIDS Research and Education, Los Angeles (J.S.C.); St. Jude Children's Research Hospital, Memphis, TN (P.M.F.); the Department of Obstetrics and Gynecology, College of Health Sciences, University of Zimbabwe, Harare (T.C.); Anova Health Institute (J.M.), Perinatal HIV Research Unit, University of the Witwatersrand, Faculty of Health Sciences (A.V.), and Empilweni Services and Research Unit (R.S.), Johannesburg, School of Public Health and Family Medicine, University of Cape Town (J.M.), and the Department of Obstetrics and Gynaecology, Stellenbosch University (G.B.T.), Cape Town, and the Centre for the AIDS Programme of Research in South Africa-Umlazi Clinical Research Site (D.M.) and Durban Paediatric HIV (R. Bobat), Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban - all in South Africa; the University of North Carolina Project, Kamuzu Central Hospital-Tidziwe Center, Lilongwe, Malawi (F.E.M.); Makerere University-Johns Hopkins University Research Collaboration, Kampala, Uganda (M.O.); the Department of Obstetrics and Gynecology, B.J. Medical College, Pune, India (R. Bhosale); the Centre for Infectious Disease Research in Zambia, Lusaka, Zambia (B.H.C.); Kilimanjaro Christian Medical Center-Duke University Collaboration, Moshi, Tanzania (P.M.); Frontier Science and Technology Research Foundation, Amherst, NY (M.B.); and the Elizabeth Glaser Pediatric AIDS Foundation, Washington, DC (L.M.M.).
Abstract
BACKGROUND: Randomized-trial data on the risks and benefits of antiretroviral therapy (ART) as compared with zidovudine and single-dose nevirapine to prevent transmission of the human immunodeficiency virus (HIV) in HIV-infected pregnant women with high CD4 counts are lacking. METHODS: We randomly assigned HIV-infected women at 14 or more weeks of gestation with CD4 counts of at least 350 cells per cubic millimeter to zidovudine and single-dose nevirapine plus a 1-to-2-week postpartum "tail" of tenofovir and emtricitabine (zidovudine alone); zidovudine, lamivudine, and lopinavir-ritonavir (zidovudine-based ART); or tenofovir, emtricitabine, and lopinavir-ritonavir (tenofovir-based ART). The primary outcomes were HIV transmission at 1 week of age in the infant and maternal and infant safety. RESULTS: The median CD4 count was 530 cells per cubic millimeter among 3490 primarily black African HIV-infected women enrolled at a median of 26 weeks of gestation (interquartile range, 21 to 30). The rate of transmission was significantly lower with ART than with zidovudine alone (0.5% in the combined ART groups vs. 1.8%; difference, -1.3 percentage points; repeated confidence interval, -2.1 to -0.4). However, the rate of maternal grade 2 to 4 adverse events was significantly higher with zidovudine-based ART than with zidovudine alone (21.1% vs. 17.3%, P=0.008), and the rate of grade 2 to 4 abnormal blood chemical values was higher with tenofovir-based ART than with zidovudine alone (2.9% vs. 0.8%, P=0.03). Adverse events did not differ significantly between the ART groups (P>0.99). A birth weight of less than 2500 g was more frequent with zidovudine-based ART than with zidovudine alone (23.0% vs. 12.0%, P<0.001) and was more frequent with tenofovir-based ART than with zidovudine alone (16.9% vs. 8.9%, P=0.004); preterm delivery before 37 weeks was more frequent with zidovudine-based ART than with zidovudine alone (20.5% vs. 13.1%, P<0.001). Tenofovir-based ART was associated with higher rates than zidovudine-based ART of very preterm delivery before 34 weeks (6.0% vs. 2.6%, P=0.04) and early infant death (4.4% vs. 0.6%, P=0.001), but there were no significant differences between tenofovir-based ART and zidovudine alone (P=0.10 and P=0.43). The rate of HIV-free survival was highest among infants whose mothers received zidovudine-based ART. CONCLUSIONS: Antenatal ART resulted in significantly lower rates of early HIV transmission than zidovudine alone but a higher risk of adverse maternal and neonatal outcomes. (Funded by the National Institutes of Health; PROMISE ClinicalTrials.gov numbers, NCT01061151 and NCT01253538 .).
RCT Entities:
BACKGROUND: Randomized-trial data on the risks and benefits of antiretroviral therapy (ART) as compared with zidovudine and single-dose nevirapine to prevent transmission of the humanimmunodeficiency virus (HIV) in HIV-infected pregnant women with high CD4 counts are lacking. METHODS: We randomly assigned HIV-infectedwomen at 14 or more weeks of gestation with CD4 counts of at least 350 cells per cubic millimeter to zidovudine and single-dose nevirapine plus a 1-to-2-week postpartum "tail" of tenofovir and emtricitabine (zidovudine alone); zidovudine, lamivudine, and lopinavir-ritonavir (zidovudine-based ART); or tenofovir, emtricitabine, and lopinavir-ritonavir (tenofovir-based ART). The primary outcomes were HIV transmission at 1 week of age in the infant and maternal and infant safety. RESULTS: The median CD4 count was 530 cells per cubic millimeter among 3490 primarily black African HIV-infectedwomen enrolled at a median of 26 weeks of gestation (interquartile range, 21 to 30). The rate of transmission was significantly lower with ART than with zidovudine alone (0.5% in the combined ART groups vs. 1.8%; difference, -1.3 percentage points; repeated confidence interval, -2.1 to -0.4). However, the rate of maternal grade 2 to 4 adverse events was significantly higher with zidovudine-based ART than with zidovudine alone (21.1% vs. 17.3%, P=0.008), and the rate of grade 2 to 4 abnormal blood chemical values was higher with tenofovir-based ART than with zidovudine alone (2.9% vs. 0.8%, P=0.03). Adverse events did not differ significantly between the ART groups (P>0.99). A birth weight of less than 2500 g was more frequent with zidovudine-based ART than with zidovudine alone (23.0% vs. 12.0%, P<0.001) and was more frequent with tenofovir-based ART than with zidovudine alone (16.9% vs. 8.9%, P=0.004); preterm delivery before 37 weeks was more frequent with zidovudine-based ART than with zidovudine alone (20.5% vs. 13.1%, P<0.001). Tenofovir-based ART was associated with higher rates than zidovudine-based ART of very preterm delivery before 34 weeks (6.0% vs. 2.6%, P=0.04) and early infant death (4.4% vs. 0.6%, P=0.001), but there were no significant differences between tenofovir-based ART and zidovudine alone (P=0.10 and P=0.43). The rate of HIV-free survival was highest among infants whose mothers received zidovudine-based ART. CONCLUSIONS: Antenatal ART resulted in significantly lower rates of early HIV transmission than zidovudine alone but a higher risk of adverse maternal and neonatal outcomes. (Funded by the National Institutes of Health; PROMISE ClinicalTrials.gov numbers, NCT01061151 and NCT01253538 .).
Authors: Alice M Stek; Mark Mirochnick; Edmund Capparelli; Brookie M Best; Chengcheng Hu; Sandra K Burchett; Carol Elgie; Diane T Holland; Elizabeth Smith; Ruth Tuomala; Amanda Cotter; Jennifer S Read Journal: AIDS Date: 2006-10-03 Impact factor: 4.177
Authors: Jens D Lundgren; Abdel G Babiker; Fred Gordin; Sean Emery; Birgit Grund; Shweta Sharma; Anchalee Avihingsanon; David A Cooper; Gerd Fätkenheuer; Josep M Llibre; Jean-Michel Molina; Paula Munderi; Mauro Schechter; Robin Wood; Karin L Klingman; Simon Collins; H Clifford Lane; Andrew N Phillips; James D Neaton Journal: N Engl J Med Date: 2015-07-20 Impact factor: 91.245
Authors: Taha E Taha; Sufia S Dadabhai; Jin Sun; M Hafizur Rahman; Johnstone Kumwenda; Newton Kumwenda Journal: J Acquir Immune Defic Syndr Date: 2012-10-01 Impact factor: 3.731
Authors: Jennifer Y Chen; Heather J Ribaudo; Sajini Souda; Natasha Parekh; Anthony Ogwu; Shahin Lockman; Kathleen Powis; Scott Dryden-Peterson; Tracy Creek; William Jimbo; Tebogo Madidimalo; Joseph Makhema; Max Essex; Roger L Shapiro Journal: J Infect Dis Date: 2012-10-12 Impact factor: 5.226
Authors: J J Kiser; M L Carten; C L Aquilante; P L Anderson; P Wolfe; T M King; T Delahunty; L R Bushman; C V Fletcher Journal: Clin Pharmacol Ther Date: 2007-06-27 Impact factor: 6.875
Authors: Li Liu; Hope L Johnson; Simon Cousens; Jamie Perin; Susana Scott; Joy E Lawn; Igor Rudan; Harry Campbell; Richard Cibulskis; Mengying Li; Colin Mathers; Robert E Black Journal: Lancet Date: 2012-05-11 Impact factor: 79.321
Authors: Joanne Katz; Anne Cc Lee; Naoko Kozuki; Joy E Lawn; Simon Cousens; Hannah Blencowe; Majid Ezzati; Zulfiqar A Bhutta; Tanya Marchant; Barbara A Willey; Linda Adair; Fernando Barros; Abdullah H Baqui; Parul Christian; Wafaie Fawzi; Rogelio Gonzalez; Jean Humphrey; Lieven Huybregts; Patrick Kolsteren; Aroonsri Mongkolchati; Luke C Mullany; Richard Ndyomugyenyi; Jyh Kae Nien; David Osrin; Dominique Roberfroid; Ayesha Sania; Christentze Schmiegelow; Mariangela F Silveira; James Tielsch; Anjana Vaidya; Sithembiso C Velaphi; Cesar G Victora; Deborah Watson-Jones; Robert E Black Journal: Lancet Date: 2013-06-06 Impact factor: 79.321
Authors: Eszter Papp; Hakimeh Mohammadi; Mona R Loutfy; Mark H Yudin; Kellie E Murphy; Sharon L Walmsley; Rajiv Shah; Jay MacGillivray; Michael Silverman; Lena Serghides Journal: J Infect Dis Date: 2014-07-16 Impact factor: 5.226
Authors: Stanzi M le Roux; Kirsten A Donald; Kirsty Brittain; Tamsin K Phillips; Allison Zerbe; Kelly K Nguyen; Andrea Strandvik; Max Kroon; Elaine J Abrams; Landon Myer Journal: AIDS Date: 2018-08-24 Impact factor: 4.177
Authors: Ross S Milne; Rachel A Silverman; Ingrid A Beck; Jennifer Mckernan-Mullin; Wenjie Deng; Thomas R Sibley; Sandra Dross; James N Kiarie; Samah R Sakr; Robert W Coombs; Michael H Chung; Lisa M Frenkel Journal: AIDS Date: 2019-05-01 Impact factor: 4.177
Authors: Catherine N Le; Paula Britto; Sean S Brummel; Risa M Hoffman; Jonathan Z Li; Patricia M Flynn; Taha E Taha; Anne Coletti; Mary Glenn Fowler; Ronald J Bosch; Rajesh T Gandhi; Karin L Klingman; James A McIntyre; Judith S Currier Journal: AIDS Date: 2019-11-15 Impact factor: 4.177
Authors: Ellen C Caniglia; Rebecca Zash; Denise L Jacobson; Modiegi Diseko; Gloria Mayondi; Shahin Lockman; Jennifer Y Chen; Mompati Mmalane; Joseph Makhema; Miguel A Hernán; Roger L Shapiro Journal: AIDS Date: 2018-01-02 Impact factor: 4.177